Vaxart, Inc. Net Fee Amt
Vaxart, Inc. (VXRT) had Net Fee Amt of $3.48 thousand as of 2026-05-07, per its S-1 filed 2026-05-08.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-08
- 2026-05-07: Net Fee Amt $3.48K.
- 2026-04-15: Net Fee Amt $24.60K.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-07 | $3.48K S-1 · filed 2026-05-08 |
| 2026-04-15 | $24.60K S-3 · filed 2026-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |